Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.37 |
| ▸ | BTK | Q06187 | 10/20 | 0.33 |
| ▸ | PARG | Q86W56 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.30 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20878498 | 0.81 | DPP4 (0.35) | DPP4DPP8DPP7BTK | |
| SCHEMBL17664669 | 0.77 | HDAC6 (0.41) | DPP4DPP8DPP7BTK | |
| SCHEMBL24061609 | 0.76 | BMP1 (0.34) | GABRA5SMYD3 | |
| SCHEMBL17660257 | 0.73 | HDAC4 (0.45) | DPP4DPP8DPP7BTKHPGD | |
| SCHEMBL17664594 | 0.73 | HDAC4 (0.45) | DPP4DPP8DPP7BTKHPGD | |
| SCHEMBL17664605 | 0.73 | BTK (0.39) | BTKGABRA5ANO1LCK | |
| SCHEMBL19891948 | 0.72 | BTK (0.41) | DPP4DPP8DPP7BTKLCK | |
| SCHEMBL24061566 | 0.72 | BTK (0.43) | DPP4DPP8DPP7BTKLCK | |
| SCHEMBL8965367 | 0.71 | DPP4 (0.39) | DPP4DPP8DPP7BTKHPGD | |
| SCHEMBL19449365 | 0.71 | DPP4 (0.39) | DPP4DPP8DPP7BTKHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3204382-B1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-12-01 | — | — | EP | disclosed |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | DPP4 2792/4885DPP8 2471/4885DPP7 2614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.